Revance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.com

Stock analysts at StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC - Get Free Report) in a research note issued to investors on Monday. The firm set a "hold" rating on the biopharmaceutical company's stock.

A number of other research analysts have also issued reports on the company. Barclays lowered their target price on Revance Therapeutics from $7.00 to $3.00 and set an "equal weight" rating on the stock in a report on Monday, December 23rd. Mizuho dropped their target price on shares of Revance Therapeutics from $6.66 to $3.10 and set a "neutral" rating on the stock in a report on Tuesday, December 10th. Needham & Company LLC restated a "hold" rating on shares of Revance Therapeutics in a report on Friday, November 8th. Finally, HC Wainwright reaffirmed a "neutral" rating and issued a $6.60 price target on shares of Revance Therapeutics in a report on Friday, November 8th. Nine research analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $8.39.

Revance Therapeutics Trading Down 4.1 %

Shares of NASDAQ:RVNC opened at $3.25 on Monday. The company has a 50 day moving average of $3.66 and a 200-day moving average of $4.54. The firm has a market cap of $339.27 million, a P/E ratio of -1.68 and a beta of 0.86. Revance Therapeutics has a twelve month low of $2.30 and a twelve month high of $7.56.

Revance Therapeutics (NASDAQ:RVNC - Get Free Report) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.02). The business had revenue of $59.88 million during the quarter, compared to analysts' expectations of $67.73 million. Equities research analysts forecast that Revance Therapeutics will post -1.57 EPS for the current year.

Hedge Funds Weigh In On Revance Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. FORA Capital LLC acquired a new stake in shares of Revance Therapeutics in the third quarter worth $54,000. Creative Planning acquired a new stake in Revance Therapeutics during the 3rd quarter worth about $56,000. Vanguard Personalized Indexing Management LLC purchased a new position in Revance Therapeutics during the 2nd quarter valued at about $33,000. Accredited Investors Inc. acquired a new position in shares of Revance Therapeutics in the 3rd quarter valued at about $67,000. Finally, Hsbc Holdings PLC purchased a new stake in shares of Revance Therapeutics in the second quarter worth approximately $38,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.